Allianz Asset Management GmbH Grows Stock Holdings in United Therapeutics Corporation (NASDAQ:UTHR)

Allianz Asset Management GmbH grew its position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 96.9% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 67,576 shares of the biotechnology company's stock after acquiring an additional 33,254 shares during the period. Allianz Asset Management GmbH owned about 0.15% of United Therapeutics worth $20,832,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of UTHR. Cerity Partners LLC lifted its stake in United Therapeutics by 30.4% in the 4th quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company's stock valued at $4,098,000 after buying an additional 2,702 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in United Therapeutics by 11.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company's stock valued at $1,129,000 after buying an additional 376 shares in the last quarter. Korea Investment CORP lifted its stake in United Therapeutics by 6.2% in the 4th quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company's stock valued at $13,863,000 after buying an additional 2,300 shares in the last quarter. Concurrent Investment Advisors LLC purchased a new position in United Therapeutics in the 1st quarter valued at about $227,000. Finally, Nepsis Inc. lifted its stake in United Therapeutics by 6.7% in the 1st quarter. Nepsis Inc. now owns 58,574 shares of the biotechnology company's stock valued at $18,057,000 after buying an additional 3,653 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR traded down $1.91 during midday trading on Friday, reaching $304.50. 310,921 shares of the stock were exchanged, compared to its average volume of 372,488. The company has a 50 day simple moving average of $300.01 and a 200 day simple moving average of $316.20. The stock has a market capitalization of $13.74 billion, a P/E ratio of 12.15, a PEG ratio of 6.68 and a beta of 0.53. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, topping analysts' consensus estimates of $6.29 by $0.34. The firm had revenue of $794.40 million during the quarter, compared to analysts' expectations of $726.82 million. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The firm's quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter last year, the company posted $6.17 EPS. On average, research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insider Activity at United Therapeutics

In related news, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction that occurred on Thursday, June 12th. The shares were sold at an average price of $279.96, for a total transaction of $3,079,560.00. Following the completion of the transaction, the executive vice president owned 36,781 shares of the company's stock, valued at approximately $10,297,208.76. This trade represents a 23.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Nilda Mesa sold 645 shares of the stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total transaction of $187,043.55. Following the transaction, the director directly owned 4,883 shares of the company's stock, valued at $1,416,021.17. The trade was a 11.67% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 81,681 shares of company stock worth $24,628,589. Company insiders own 10.30% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on UTHR. Wall Street Zen lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Morgan Stanley decreased their price target on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 10th. UBS Group decreased their price target on shares of United Therapeutics from $410.00 to $385.00 and set a "buy" rating on the stock in a research note on Monday, June 30th. Cantor Fitzgerald assumed coverage on shares of United Therapeutics in a report on Monday, June 2nd. They issued an "overweight" rating and a $405.00 price objective for the company. Finally, Wells Fargo & Company reiterated an "equal weight" rating and issued a $314.00 price objective (down previously from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $383.08.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.